A redox-based system that enhances delivery of estradiol to the brain : pharmacokinetic evaluation in the dog

• Published in: Pharmaceutical research 1990-08, Vol.7 (8), p.879-883
• Main Authors: DIETZEL, K, KEUTH, V, ESTES, K. S, BREWSTER, M. E, CLEMMONS, R. M, VISTELLE, R, BODOR, N. S, DERENDORF, H
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Blood Proteins - metabolism; Brain - metabolism; Dogs; Drug Stability; Estradiol - pharmacokinetics; Hormones. Endocrine system; Male; Medical sciences; Oxidation-Reduction; Pharmacology. Drug treatments; Protein Binding
• ISSN: 0724-8741; 1573-904X
• DOI: 10.1023/A:1015977319212

The pharmacokinetics of a dihydropyridine-pyridinium salt-type chemical delivery system (CDS) for brain-targeted delivery of estradiol (E2) were examined in dogs. Parameters evaluated in vitro included stability in buffers and biological fluids and plasma protein binding. In vivo studies examined drug and metabolite concentrations in plasma, urine, and cerebrospinal fluid as well as in selected brain regions. The administered lipophilic E2-CDS disappeared very quickly from plasma and was not detected in urine. The oxidized drug form, E2-Q+, was excreted unchanged or as a conjugate in the urine for as long as 2 weeks. Plasma levels were below assay detection limits at later times. Pharmacokinetic analysis of urine E2-Q+ levels allowed estimation of a half-life of 2.2 days. Amounts of E2-Q+ excreted into the urine were proportional to the dose but averaged only 13.9% of the dose, indicating that other routes of excretion must be considered. CSF levels were below the limit of detection for both E2-CDS and E2-Q+, however, brain tissue concentrations of E2-Q+ were similar in several brain regions of individual animals examined 1 or 3 days after drug dosing.